Kinsella, M., Halliday, L. O. E., Shaw, M., Capel, Y., Nelson, S. M. and Kearns, R. J. (2022) Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis. Substance Use and Misuse, 57(9), pp. 1400-1416. (doi: 10.1080/10826084.2022.2083174) (PMID:35758300)
Text
271775.pdf - Published Version Available under License Creative Commons Attribution. 2MB | |
Text
271775Suppl1.pdf - Supplemental Material 2MB | |
Text
271775Suppl2.pdf - Supplemental Material 714kB |
Abstract
Introduction: Illicit opioid use in pregnancy is associated with adverse maternal, neonatal, and childhood outcomes. Opioid substitution is recommended, but whether methadone or buprenorphine is the optimal agent remains unclear. Methods: We searched EMBASE, PubMed, Web of Science, Scopus, Open Gray, CINAHL and the Cochrane Central Registry of Controlled Trials (CENTRAL) from inception to April 2020 for randomized controlled trials (RCTs) and cohort studies comparing methadone and buprenorphine treatment for opioid-using mothers. Included studies assessed maternal and or neonatal outcomes. We used random-effects meta-analyses to estimate summary measures for outcomes and report these separately for RCTs and cohort studies. Results: Of 408 abstracts screened, 20 papers were included (4 RCTs, 16 cohort, 223 and 7028 participants respectively). All RCTs (4/4) had a high risk of bias and median (IQR) Newcastle Ottawa Scale for cohort studies was 7.5 (6–9). In both RCTs and cohort studies, buprenorphine was associated with; greater offspring birth weight (weighted mean difference [WMD] 343 g (95% CI: 40–645 g) in RCT and 184 g (95% CI: 121–247 g) in cohort studies); body length at birth (WMD 2.28 cm (95% CI: 1.06–3.49 cm) in RCTs and 0.65 cm (95% CI: 0.31–0.98 cm) in cohort studies); and reduced risk of prematurity (risk ratio [RR] 0.41 (95% CI: 0.18–0.93) in RCTs and 0.63 [95% CI: 0.53–0.75] in cohort studies) when compared to methadone. All other clinical outcomes were comparable. Conclusions: Compared to methadone, buprenorphine was consistently associated with improved birthweight and gestational age, however given potential biases, results should be interpreted with caution.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Kearns, Dr Rachel and Kinsella, Dr Michael and Nelson, Professor Scott and Halliday, Dr Lucy and Shaw, Dr Martin |
Authors: | Kinsella, M., Halliday, L. O. E., Shaw, M., Capel, Y., Nelson, S. M., and Kearns, R. J. |
College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
Journal Name: | Substance Use and Misuse |
Publisher: | Taylor & Francis |
ISSN: | 1082-6084 |
ISSN (Online): | 1532-2491 |
Published Online: | 25 June 2022 |
Copyright Holders: | Copyright © 2022 The Authors |
First Published: | First published in Substance Use and Misuse 57(9): 1400-1416 |
Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record